argenex (NASDAQ:ARGX) Stock Gets Price Target Cut from Wells Fargo & Company

argenex (NASDAQ:ARGX) had its price target cut by Wells Fargo & Company from $1,356.00 to $1,336.00 in a report issued on Friday,Benzinga reports. They currently have an overweight rating on the stock.

Other equities research analysts have also issued reports about the company. Wedbush dropped their price target on argenex from $1,150.00 to $1,130.00 and set an “outperform” rating on the stock in a research report on Thursday, October 8th. Robert W. Baird increased their price objective on argenex from $823.00 to $861.00 and gave the stock a “neutral” rating in a report on Friday. DZ Bank reissued a “buy” rating on shares of argenex in a research report on Friday, October 9th. UBS Group upgraded shares of argenex from a “neutral” rating to a “buy” rating and boosted their target price for the company from $960.00 to $1,400.00 in a report on Wednesday, August 26th. Finally, Truist Financial upped their target price on shares of argenex from $1,030.00 to $1,095.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, argenex has a consensus rating of “Moderate Buy” and a consensus target price of $1,142.37.

argenex Price Performance

Shares of ARGX opened at $873.71 on Friday. argenex has a one year low of $661.85 and a one year high of $1,072.75. The company has a 50-day simple moving average of $956.62 and a two-hundred day simple moving average of $886.34. The firm has a market capitalization of $54.95 billion, a PE ratio of 30.49, a price-to-earnings-growth ratio of 0.89 and a beta of 0.44.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Friday, October 23rd. The company reported $7.80 earnings per share for the quarter, beating the consensus estimate of $7.44 by $0.36. argenex had a return on equity of 47.70% and a net margin of 31.66%. The business had revenue of $1.75 billion for the quarter. Analysts expect that argenex will post 25.79 EPS for the current fiscal year.

Institutional Investors Weigh In On argenex

Institutional investors have recently modified their holdings of the stock. Whipplewood Advisors LLC bought a new position in shares of argenex during the first quarter valued at $28,000. Eastern Bank purchased a new position in shares of argenex in the 2nd quarter worth about $32,000. Axiom Investment Management LLC purchased a new position in shares of argenex in the 1st quarter worth about $50,000. WPG Advisers LLC boosted its stake in argenex by 17.8% in the 1st quarter. WPG Advisers LLC now owns 86 shares of the company’s stock worth $63,000 after purchasing an additional 13 shares in the last quarter. Finally, Mather Group LLC. boosted its stake in argenex by 19.1% in the 3rd quarter. Mather Group LLC. now owns 81 shares of the company’s stock worth $78,000 after purchasing an additional 13 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

More argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Strong quarterly results: argenx reported $7.80 in EPS, exceeding the $7.44 consensus estimate, while revenue reached $1.75 billion. Product net sales grew 54% year over year to $1.7 billion, and operating profit was $486 million. argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Bullish analyst support: Morgan Stanley raised its price target from $1,140 to $1,190 and maintained an “overweight” rating. Wells Fargo also maintained “overweight” despite trimming its target from $1,356 to $1,336. Jefferies called the post-news setup a potentially attractive entry point. Morgan Stanley rating
• Neutral Sentiment: Targets remain above the market price, but revisions are mixed: Guggenheim lowered its target from $1,185 to $1,120 while keeping a “buy” rating. Robert W. Baird raised its target from $823 to $861 but retained a “neutral” rating, and RBC reportedly cut its target. These changes suggest continued confidence in long-term value but more cautious near-term expectations. Guggenheim rating
• Negative Sentiment: Clinical-development setback is overshadowing the earnings beat: Reports highlighted a surprise testing setback for argenx’s core drug, raising concerns about future growth, product expansion and execution. That issue appears to be driving the weaker investor reaction despite the company’s strong sales and profitability. argenx testing setback

About argenex

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.